A short and readable commentary on monoclonal antibodies and dyslipidaemias, particularly on FOURIER, SPIRE and ODYSSEY trials
You are here:
PCSK9 Inhibition to Reduce Cardiovascular Risk: Tempering Expectations
Submitted by: Aristotle Protopapas
Source: Circulation Research
Keywords:
Author(s): David D. Waters, Priscilla Y. Hsue
